Project rebuild the evidence base (REB): A method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.

Autor:	Boussageon R; Collège universitaire de médecine générale, UCBL, Lyon 1, 69000 Lyon, France; UMR 5558, LBBE - EMET, CNRS-UCBL, Lyon 1, 69000 Lyon, France; Conseil scientifique du CNGE, 75000 Paris, France., Blanchard C; Department of general practice, Poitiers University, 15, rue de l'Hôtel Dieu TSA 71117, 86073 Poitiers, France. Electronic address: Cla.blanchard@gmail.com., Charuel E; Department of General Practice and Research Unit ACCePPT, Clermont Auvergne University, 63001 Clermont-Ferrand, France., Menini T; Department of General Practice and Research Unit ACCePPT, Clermont Auvergne University, 63001 Clermont-Ferrand, France., Pereira B; CHU Clermont-Ferrand, Biostatistics Unit (Department of Clinical research and Innovation), 63000 Clermont-Ferrand, France., Naudet F; University of Rennes, CHU Rennes, Inserm, CIC 1414 (centre d'investigation clinique de Rennes), 35000 Rennes, France., Kassai B; UMR 5558, LBBE - EMET, CNRS-UCBL, Lyon 1, 69000 Lyon, France., Gueyffier F; UMR 5558, LBBE - EMET, CNRS-UCBL, Lyon 1, 69000 Lyon, France., Cucherat M; UMR 5558, LBBE - EMET, CNRS-UCBL, Lyon 1, 69000 Lyon, France., Vaillant-Roussel H; Department of General Practice and Research Unit ACCePPT, Clermont Auvergne University, 63001 Clermont-Ferrand, France.
Jazyk:	angličtina
Zdroj:	Therapie [Therapie] 2023 Jul-Aug; Vol. 78 (4), pp. 353-365. Date of Electronic Publication: 2022 Oct 20.
DOI:	10.1016/j.therap.2022.10.008
Abstrakt:	Evidence-based medicine is the cornerstone of shared-decision making in healthcare today. The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet today, many drugs are prescribed and used without solid evidence of efficacy. Clinical trials and randomised clinical trials (RCTs) are the best method to evaluate drug efficacy and side effects. In a shared medical decision-making approach, general practitioners need drug assessment based on patient-important outcomes. The aim of project rebuild the evidence base (REB) is to bridge the gap between the data needed in clinical practice and the data available from clinical research. The drugs will be assessed on clinical patient important outcomes and for a population. Using the Cochrane tools, we propose to analyse for each population and outcome: 1) a meta-analysis based on RCTs with a low risk of bias overall; 2) an evaluation of results of confirmatory RCTs; 3) a statistical analysis of heterrogeneity between RCTs and 4) an analysis of publication bias. Depending on the results of these analyses, the evidence will be categorized in 4 different levels: firm evidence, evidence (to be confirmed), signal or absence of evidence. Project REB proposes a method for reading and interpreting RCTs and their meta-analysis to produce quality data for general practitioners to focus on risk-benefit assessment in the interest of patients. If this data does not exist, it could enable clinical research to better its aim. (Copyright © 2022 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu